Autologous stem cell therapy for premature ovarian failure is relatively underdeveloped in China, and there is no clear data on how long it can be realized. According to the current clinical data, autologous stem cell therapy for premature ovarian failure can improve the discomfort caused by premature ovarian failure, but it can not completely reverse premature ovarian failure. Autologous stem cell treatment for premature ovarian failure is generally done by inputting cells into blood vessels and transplanting them into the tissues of the ovary, using the stem cells’ own renewal and differentiation to promote ovarian cell generation and improve ovarian function. The newborn ovarian cells can improve a series of uncomfortable symptoms caused by premature ovarian failure through the production of estrogen, which can improve the quality of life of women, improve fertility and so on. However, since autologous stem cell transplantation treatment technology is relatively underdeveloped, it is necessary to choose a specialized hospital for treatment.